Novel therapeutic options have significantly improved survival and long-term outcomes in
many cancer entities. Unfortunately, this improvement in outcome is often accompanied by …

Heart failure (HF) is the end-stage of all heart disease and arguably constitutes the greatest
unmet therapeutic need in cardiovascular medicine today. Classic epidemiological studies …

Ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM) are the two primary
etiologies of end-stage heart failure. However, there remains a dearth of comprehensive …

Circulating protein biomarkers provide information regarding pathways in heart failure (HF)
and can add important value to clinicians. Advancements in proteomics allow researchers to …

In recent years, apoptosis has increasingly drawn the attention of both oncologists and
cardiologists alike. Anticancer treatment is possible by induction of apoptosis in cancer cells …

Aims Cardiac specificity provides an advantage in correlating heart failure (HF) biomarker
plasma levels with indices of cardiac function and remodelling, as shown for natriuretic …

Chemotherapy, radiotherapy, targeted therapy, and immunotherapy have brought hope to
cancer patients. With the prolongation of survival of cancer patients and increased clinical …

Chronic anthracycline cardiotoxicity is a feared complication of cancer chemotherapy.
However, despite several decades of primarily hypothesis-driven research, the molecular …

BACKGROUND: To date, gene expression studies related to chronic heart failure (CHF)
have mainly involved microarray analysis of myocardial tissues. The potential utility of blood …

In the current study we examined several proteomic-and RNA-Seq-based datasets of
cardiac-enriched, cell-surface and membrane-associated proteins in human fetal and …